The boom in weight-loss drugs risks creating social inequities, experts warn. “For all, or for the elite?”

Digi 24

Center

Factuality

Ownership

Strong weight loss medications, such as Ozempic, the revolutionary treatment for type 2 diabetes, and the obesity medication Wegovy, both developed by the Danish company Novo Nordisk, came into the public's focus last year, offering a new way to address record obesity rates. However, their extraordinary demand and high prices will keep them away from many patients who could benefit from them in 2024, creating social inequalities, comments Reuter…